HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry

• HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin on October 6, 2025.
• HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved remission outcomes, supporting label advancement and access growth. This is one of the world's first examples of using AI to generate this kind of regulatory-grade RWD for these types of applications.
• AI-driven real-world data (RWD) and real-world evidence (RWE) generation capability for these types of applications is globally unique to HEALWELL and is expected to be an important driver for both clinical and commercial value.
• HEALWELL continues to earn global recognition for its leadership in healthcare AI, being named a finalist in Newsweek's inaugural AI Impact Awards 2025 for advancing validated, ethical AI that drives measurable clinical and commercial impact.

Toronto, Ontario--(Newsfile Corp. - October 21, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that HEALWELL's DARWEN™ AI Platform has demonstrated one of world's first examples of using AI to generate real world data (RWD) for supporting greater patient access, product advancement & reimbursement growth for the pharmaceutical industry. AI-driven real-world data (RWD) and real-world evidence (RWE) generation capability for these types of applications is globally unique to HEALWELL and is expected to be an important driver for both clinical and commercial value.

On October 6^th 2025, HEALWELL in collaboration with Takeda Pharmaceutical (a top 20 global pharmaceutical company¹) presented new AI generated and regulatory-grade real-world data (RWD) and real-world evidence (RWE) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin. HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved remission outcomes, supporting label advancement and access growth. Ultimately the real-world data generated provided evidence that demonstrated remission improvement outcomes; an important outcome to drive improved patient outcomes in a disease area that has significant population burden. Inflammatory bowel disease affects approximately 2.39 million people in the United States² and nearly 400,000 people in Canada³.

Schreibe Deinen Kommentar